JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

IQVIA Holdings Inc

Open

BrancheGesundheitswesen

158.59 0.08

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

153.65

Max

159.22

Schlüsselkennzahlen

By Trading Economics

Einkommen

182M

514M

Verkäufe

264M

4.4B

KGV

Branchendurchschnitt

20.898

67.147

Gewinnspanne

11.778

Angestellte

93,000

EBITDA

1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+41.24% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-12B

28B

Vorheriger Eröffnungskurs

158.51

Vorheriger Schlusskurs

158.59

Nachrichtenstimmung

By Acuity

50%

50%

201 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

IQVIA Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Apr. 2026, 23:53 UTC

Ergebnisse

Naver Posts Weaker First-Quarter Earnings

29. Apr. 2026, 23:41 UTC

Heiße Aktien

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. Apr. 2026, 23:55 UTC

Ergebnisse

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. Apr. 2026, 23:54 UTC

Ergebnisse

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. Apr. 2026, 23:52 UTC

Ergebnisse

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. Apr. 2026, 23:51 UTC

Ergebnisse

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. Apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan 1Q Net CNY1.70B, Down 14%

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan: Power Generation Down 2.9% as of End-March

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss Narrows>000002.SZ

29. Apr. 2026, 23:18 UTC

Ergebnisse

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. Apr. 2026, 23:17 UTC

Ergebnisse

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. Apr. 2026, 23:13 UTC

Ergebnisse

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. Apr. 2026, 23:12 UTC

Ergebnisse

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. Apr. 2026, 23:04 UTC

Ergebnisse

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. Apr. 2026, 23:04 UTC

Ergebnisse

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer-Vergleich

Kursveränderung

IQVIA Holdings Inc Prognose

Kursziel

By TipRanks

41.24% Vorteil

12-Monats-Prognose

Durchschnitt 224.54 USD  41.24%

Hoch 255 USD

Tief 185 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für IQVIA Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

14

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

150.68 / 153.45Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

201 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat